ArticleBMC cardiovascular disorders2025
Early impact of CytoSorb® adsorber on proinflammatory cytokine plasmatic levels in a porcine model of refractory cardiogenic shock supported with VA-ECMO.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiogenic shock (CS) is a pejorative situation which often requires a circulatory support with VA-ECMO. However, VA-ECMO is known to trigger an inflammatory cascade with expression of proinflammatory cytokines Interleukin-6 (IL-6) and Interleukin-10 (IL-10) causing organ damages and hemodynamic deterioration. Cytokine adsorption using the CytoSorb® adsorber was recently proposed to mitigate the inflammatory response. As relevance of implementing CytoSorb® adsorber with VA-ECMO is not validated, we sought to assess whether it might early influence levels of IL-6 and IL-10 in a porcine model of ischemic refractory CS. MATERIALS AND
methodsCS was induced in 12 male pigs following acute proximal occlusion of the left anterior descending artery (LAD). After a low-flow period of 60 min, circulatory support with VA-ECMO was initiated and pigs were randomly assigned in two groups, CytoSorb® (-) (VA-ECMO without CytoSorb® adsorber: n = 6) and CytoSorb® (+) (VA-ECMO with CytoSorb® adsorber: n = 6). In each group, modulation of IL-6 and IL-10 was assessed during a four-hour procedure, as well as impact on arterial blood pressure, biological and biochemical, parameters.
resultsAfter 240 min, the Group CytoSorb® (+) demonstrated a significant propensity to reduce levels of IL-10, (p = 0.0421*). Regarding hemodynamics, biological and biochemical parameters, Cytosorb® adsorber showed no difference with the group CytoSorb® (-).
conclusionsDespite encouraging early benefits, further studies are still necessary to validate interests of a routine use of CytoSorb® adsorber with VA-ECMO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.